Loading patent…
AssigneeChangchun Genescience Pharmaceutical Co., Ltd.
InventorsXiao FENG, Lei JIN, Liang XIAO, Tao WANG, Suofu QIN
Estimating the term…
An anti-CD47 monoclonal antibody and use thereof. The provided anti-CD47 monoclonal antibody can effectively inhibit tumor growth. Blocking human SIRP and human CD47 signals may enhance macrophage phagocytosis of tumor cells, prevent the tumor cells from escaping a tumor immune defense system, and have an anti-tumor function. Blocking association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface may block a “do not eat me” signal from the tumor cells, promoting tumor cell recognition and uptake of macrophages, and thereby facilitating tumor cells to be phagocytosed. The association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface is a common “do not eat me” signal. The anti-CD47 antibody, as a very promising target in the tumor immune system, will play a powerful and effective role in human cancer therapy.
An anti-CD47 monoclonal antibody, wherein, the hypervariable regions of the heavy chain variable region are HVR-H1, HVR-H2, and HVR-H3, the hypervariable region HVR-H1 sequence being represented by SEQ ID NO:
An anti-CD47 monoclonal antibody, wherein the hypervariable regions of the heavy chain variable region are HVR-H1, HVR-H2, and HVR-H3, the hypervariable region HVR-H1 sequence being represented by SEQ ID NO:
An anti-CD47 monoclonal antibody, wherein, the hypervariable regions of the heavy chain variable region are HVR-H1, HVR-H2, and HVR-H3, the hypervariable region HVR-H1 sequence being represented by SEQ ID NO:
Dependencies are inferred from the claim text.